Cargando…
Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
Targeted inhibitors of JAK2 (eg ruxolitinib) often provide symptomatic relief for myeloproliferative neoplasm (MPN) patients, but the malignant clone persists and remains susceptible to disease transformation. These observations suggest that targeting alternative dysregulated signaling pathways may...
Autores principales: | Kong, Tim, Laranjeira, Angelo B.A., Collins, Taylor B., De Togni, Elisa S., Wong, Abigail J., Fulbright, Mary C., Ruzinova, Marianna, Celik, Hamza, Challen, Grant A., Fisher, Daniel A.C., Oh, Stephen T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791597/ https://www.ncbi.nlm.nih.gov/pubmed/34644371 http://dx.doi.org/10.1182/bloodadvances.2020002804 |
Ejemplares similares
-
PD-1 inhibition in advanced myeloproliferative neoplasms
por: Hobbs, Gabriela, et al.
Publicado: (2021) -
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
por: Pecquet, Christian, et al.
Publicado: (2023) -
Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study
por: Tuyet Kristensen, Daniel, et al.
Publicado: (2023) -
Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens
por: Seetharam, Sumanth Mosale, et al.
Publicado: (2023) -
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies
por: Gorak, Edward J., et al.
Publicado: (2023)